Abstract
With almost 40 million people infected with human immunodeficiency virus (HIV), it is one of the most devastating diseases with no cure in sight. Over the past two decades, significant progress has been made to identify and validate drug targets for HIV. However, most of the 20 FDA approved drugs are targeted to two enzymes; reverse transcriptase and protease. Other drug targets derived from HIV and host factors are being validated, and novel compounds are being developed to overcome drug resistance. Recent data indicate that low and residual virus found in tissues of the lymphoid and central nervous system (CNS) is likely due to insufficient drug levels. Thus, improvement in the delivery of anti-HIV drugs to these tissues with limited drug penetration or accumulation, is equally important to maximally suppress viral replication. Novel lipid associated drugs (i.e. indinavir) targeted to the lymphoid tissue have been shown to overcome limited drug exposure in the lymph nodes and to further reduce residual virus in tissue. This review discusses viral and cellular targets that could interrupt viral replication, as well as novel and proven strategies to enhance the delivery of anti-HIV drugs to the lymphoid, CNS, and cells where low viral replication and limited drug levels exist.
Keywords: HIV, selective delivery, cellular targets, HAART, viral latency
Infectious Disorders - Drug Targets
Title: Recent Developments in Drug Targets and Delivery of Anti-HIV Drugs
Volume: 6 Issue: 2
Author(s): Noha N. Salama, Aaron Endsley and Rodney J.Y Ho
Affiliation:
Keywords: HIV, selective delivery, cellular targets, HAART, viral latency
Abstract: With almost 40 million people infected with human immunodeficiency virus (HIV), it is one of the most devastating diseases with no cure in sight. Over the past two decades, significant progress has been made to identify and validate drug targets for HIV. However, most of the 20 FDA approved drugs are targeted to two enzymes; reverse transcriptase and protease. Other drug targets derived from HIV and host factors are being validated, and novel compounds are being developed to overcome drug resistance. Recent data indicate that low and residual virus found in tissues of the lymphoid and central nervous system (CNS) is likely due to insufficient drug levels. Thus, improvement in the delivery of anti-HIV drugs to these tissues with limited drug penetration or accumulation, is equally important to maximally suppress viral replication. Novel lipid associated drugs (i.e. indinavir) targeted to the lymphoid tissue have been shown to overcome limited drug exposure in the lymph nodes and to further reduce residual virus in tissue. This review discusses viral and cellular targets that could interrupt viral replication, as well as novel and proven strategies to enhance the delivery of anti-HIV drugs to the lymphoid, CNS, and cells where low viral replication and limited drug levels exist.
Export Options
About this article
Cite this article as:
Salama N. Noha, Endsley Aaron and Ho J.Y Rodney, Recent Developments in Drug Targets and Delivery of Anti-HIV Drugs, Infectious Disorders - Drug Targets 2006; 6 (2) . https://dx.doi.org/10.2174/187152606784112137
DOI https://dx.doi.org/10.2174/187152606784112137 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Age-related Changes in Pharmacodynamics: Focus on Drugs Acting on Central Nervous and Cardiovascular Systems
Current Drug Metabolism Preclinical Analyses of the Therapeutic Potential of Allopregnanolone to Promote Neurogenesis In Vitro and In Vivo in Transgenic Mouse Model of Alzheimers Disease
Current Alzheimer Research New Technologies for Drug Delivery Across the Blood Brain Barrier
Current Pharmaceutical Design Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection
Current Pharmaceutical Design BACE1 Deficient Mice: Their Role in Drug Target Validation and Implications for Alzheimers Disease Therapies
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Evidence of Redox Unbalance in Post-Acute Ischemic Stroke Patients
Current Neurovascular Research Delayed Neuroleptic Malignant Syndrome Associated with the Use of Low Dose Risperidone in Conjunction with Cholinergic Drugs-the Dangers of Polypharmacy in the Elderly
Current Drug Therapy Conditioned Avoidance Response in the Development of New Antipsychotics
Current Pharmaceutical Design Mechanisms of ERK1/2 Regulation by Seven-Transmembrane-Domain Receptors
Current Pharmaceutical Design The Mechanism of Memory Impairment Induced by Aβ Chronic Administration Involves Imbalance between Cytokines and Neurotrophins in the Rat Hippocampus
Current Alzheimer Research Quantitative μPET Imaging of Cerebral Glucose Metabolism and Amyloidosis in the TASTPM Double Transgenic Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Editorial (Thematic Issue: Health Impact and Management of a Disrupted Circadian Rhythm and Sleep in Critical Illnesses)
Current Pharmaceutical Design Importance of P-gp PET Imaging in Pharmacology
Current Pharmaceutical Design Modulation of Microglial Innate Immunity in Alzheimers Disease by Activation of Peroxisome Proliferator-activated Receptor Gamma
Current Medicinal Chemistry Neuroprotective Strategies for Parkinsons Disease
Current Neuropharmacology Potential Therapeutic Interest of Adenosine A2A Receptors in Psychiatric Disorders
Current Pharmaceutical Design Potential Role of Inflammation in Associations between Particulate Matter and Heart Failure
Current Pharmaceutical Design Neuroprotective Effects of Agomelatine and Vinpocetine Against Chronic Cerebral Hypoperfusion Induced Vascular Dementia
Current Neurovascular Research Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease
Current Pharmaceutical Design Recent Advancements in Nanodiamond Mediated Brain Targeted Drug Delivery and Bioimaging of Brain Ailments: A Holistic Review
Pharmaceutical Nanotechnology